【科技日报】新型试剂盒能捕捉早期肺癌“分子信号”

Core Insights - The research team led by Hu Haike from the Hangzhou Institute of Medicine has developed the world's first diagnostic kit for distinguishing between benign and malignant lung nodules, which has received regulatory approval as a Class III medical device in China [1][2] - Lung cancer remains the most prevalent and deadly cancer in China, with approximately 150 million people suffering from lung nodules, of which over 95% are benign [1][2] Group 1 - The diagnostic kit is expected to significantly improve early detection rates of lung cancer, addressing a critical challenge in reducing lung cancer mortality [2][3] - The team has focused on the early diagnosis of lung cancer since 2016, utilizing a large cancer tissue library and advanced screening technologies to identify specific biomarkers [2] - The kit has shown a sensitivity of over 65% for early lung cancer detection, with an accuracy rate exceeding 85% when used alongside low-dose spiral CT for atypical small nodules [2] Group 2 - The kit is anticipated to be launched in the market after the Spring Festival, providing essential support for China's "Healthy China 2030" cancer early screening strategy [3]